Regenxbio Inc. (RGNX) Shares Down 2.3%
Regenxbio Inc. (NASDAQ:RGNX)’s share price traded down 2.3% during trading on Monday . The stock traded as low as $7.52 and last traded at $7.74, with a volume of 126,877 shares trading hands. The stock had previously closed at $7.92.
Several equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Morgan Stanley upped their price target on shares of Regenxbio from $34.00 to $36.00 in a research note on Friday, April 8th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $33.00 price objective on shares of Regenxbio in a research note on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $28.35.
The stock’s market cap is $204.65 million. The stock has a 50 day moving average price of $9.08 and a 200 day moving average price of $11.32.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.01. Analysts predict that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.
In other Regenxbio news, insider Fmr Llc sold 33,196 shares of the business’s stock in a transaction dated Thursday, April 28th. The stock was sold at an average price of $11.23, for a total transaction of $372,791.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.